Solutions

Public health

Improve population health and advance patient care

Utilize real-world data, powerful analytics, and the Truveta Language Model to advance public health

How we can help

Safety

Monitor patient access and therapy responses with research-ready data, updated daily for real-time insights.

  • Quickly assess emerging safety signals with real-time data 
  • Quantify rates of adverse events for any therapeutic 
  • Assess how safety signals differ by clinical or demographic groups 
  • Conduct studies assessing the long-term safety of different treatments
  • Monitor post-approval safety and outcomes for any drug or device
  • Assess safety of medications in pregnant women and their infants 

Assessing the safety of novel interventions

Comparative bleeding incidence 7 days post-procedure for pulmonary embolism interventions

 Read the research

Comparative effectiveness

Assess the clinical and cost-effectiveness of products by leveraging real-world data from over 120 million patients to drive meaningful differentiation. 

  • Assess treatment efficacy with timely, patient-level outcomes and SDOH data
  • Monitor performance of different therapeutics in real-world clinical environments 
  • Analyze how access and utilization differ between groups and across geographies 
  • Compare disease progression and treatment with access to longitudinal, complete data
  • Understand treatment response across diverse patient populations 
  • Guide policy and reimbursement decisions with access to complete clinical data

Comparing effectiveness of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss

Comparing mean percentage body weight loss for patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro)

 Read the research

Clinical research

Supplement regulatory decision making with data from real-world clinical settings.

  • Supplement trial insights with real-world control arms
  • De-risk regulatory decisions with dynamic, real-time analytics
  • Understand variations in trial site and participants
  • Support and assess regulatory decisions with access to daily-updated data  

De-risking clinical trials by dynamically testing inclusion/exclusion (I/E) criteria In partnership with STAT News, Truveta Research explored trends in the incidence of testing and diagnosis of PVD/PAD among U.S. patients aged 50 years and older from 2018 to 2024.Understanding the incindence of testing and diagnosis of PVD/PAD by selected patient characteristics

 Read the research

Population health

Monitor population health trends, access to care, and respond to emerging health threats 

  • Perform real-time surveillance of screening, diagnoses, and treatment patterns 
  • Prepare rapid response programs with real-time monitoring across demographics and geographies
  • Monitor drug shortages and identify trends in drug prescriptions and fill rates 
  • Guide resource allocation, evaluate policy, and identify disparities in access and outcomes
  • Evaluate AI model accuracy and representativeness over time with representative, real-world data

Assessing the impact of drug shortagesRate of ampheatmine/dextroamphetamine prescription fills per eligible population

 Read the research

Care quality

Monitor population health trends, identify gaps in access to treatment, and inform policy.

  • Assess outcomes of treatments or interventions to inform public policy
  • Discover patterns or gaps in care quality across demographic groups
  • Design and validate new guidelines and quality measures using granular clinical data  
  • Identify and analyze quality indicators to evaluate policy effectiveness
  • Inform value-based care models with access to real-time data across care settings

Understanding risk of breakthrough infection and hospitalization across populations

Hazard ratio of breakthrough COVID-19 infection associated with a combination of comorbidities


 Read the research

How we can help

Safety

Comparative effectiveness

Clinical research

Population health

Care quality

Safety

Monitor patient access and therapy responses with research-ready data, updated daily for real-time insights.

^
Quickly assess emerging safety signals with real-time data
^
Quantify rates of adverse events for any therapeutic
^
Assess how safety signals differ by clinical or demographic groups
^
Conduct studies assessing the long-term safety of different treatments
^
Monitor post-approval safety and outcomes for any drug or device
^
Assess safety of medications in pregnant women and their infants
Assessing the safety of novel interventions
Comparison table from a scientific publication using Truveta Data to illustrate bleeding events associated with two medical devices for treating pulmonary embolism: the USCDT (Unspecified Superiority Clot Dissolver) and MT (Standard Mechanical Thrombectomy). The data is presented for two distinct time periods—2009 to 2023 (primary analysis) and 2018 to 2023 (contemporary analysis). Bleeding events are categorized into six types, with results presented as counts and percentages. Statistical significance is indicated by p-values, providing insights into the safety profiles of the two devices over time.
 Comparative bleeding incidence 7 days post-procedure for pulmonary embolism interventions

Comparative effectiveness

Assess the clinical and cost-effectiveness of products by leveraging real-world data from over 120 million patients to drive meaningful differentiation. 

^

Assess treatment efficacy with timely, patient-level outcomes and SDOH data 

^

Monitor performance of different therapeutics in real-world clinical environments

^

Analyze how access and utilization differ between groups and across geographies 

^

Compare disease progression and treatment with access to longitudinal, complete data 

^

Understand treatment response across diverse patient populations

^

Guide policy and reimbursement decisions with access to complete clinical data

Comparing effectiveness of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss
October 2023 Respiratory Viruses hospitalizations trend report
Comparing mean percentage body weight loss for patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro)

Clinical research

Supplement regulatory decision making with data from real-world clinical settings.

^
Supplement trial insights with real-world control arms
^
De-risk regulatory decisions with dynamic, real-time analytics 
^
Understand variations in trial site and participants  
^
Support and assess regulatory decisions with access to daily-updated data 
De-risking clinical trials by dynamically testing inclusion/exclusion (I/E) criteria
In partnership with STAT News, Truveta Research explored trends in the incidence of testing and diagnosis of PVD/PAD among U.S. patients aged 50 years and older from 2018 to 2024.
Understanding the incidence of testing and diagnosis of PVD/PAD by selected patient characteristics

Population health

Monitor population health trends, access to care, and respond to emerging health threats

^
Perform real-time surveillance of screening, diagnoses, and treatment patterns
^
Prepare rapid response programs with real-time monitoring across demographics and geographies
^

Monitor drug shortages and identify trends in drug prescriptions and fill rates

^

Guide resource allocation, evaluate policy, and identify disparities in access and outcomes   

^

Evaluate AI model accuracy and representativeness over time with representative, real-world data

Assessing the impact of drug shortages
Truveta Research uses EHR data to explore trends in monthly respiratory virus-associated hospitalizations for RSV, COVID, influenza, parainfluenza, HMPV, and rhinovirus.
Rate of amphetamine/dextroamphetamine prescription fills per eligible population

Care quality

Monitor population health trends, identify gaps in access to treatment, and inform policy.

^
Assess outcomes of treatments or interventions to inform public policy
^
Discover patterns or gaps in care quality across demographic groups
^

Design and validate new guidelines and quality measures using granular clinical data

^
Identify and analyze quality indicators to evaluate policy effectiveness
^
Inform value-based care models with access to real-time data across care settings
Understanding risk of breakthrough infection and hospitalization across populations
Presented at ICPE 2024, Truveta Research explores the time to potassium-lowering drugs after removal of race from CKD-EPI creatinine equation.
Hazard ratio of breakthrough COVID-19 infection associated with a combination of comorbidities

Why Truveta

Complete EHR data

Truveta offers complete and clean EHR data linked with SDOH, mortality, and claims data, with rigorous standards for data quality.

Representative data, updated daily

Truveta Data is updated daily from health systems, representing the full diversity of the US.

Mother-child data

Access longitudinal EHR data for more than 1 million mother-child pairs, enabling research from pregnancy through the first 5 years of the child’s life.

Trusted by leading life science, public health, healthcare, and academic research organizations